JAMA Dermatology Most Cited
//www.igerbera.com/journals/jamadermatology
The Most Cited articles published by JAMA Dermatology
en-us
Tue, 07 Mar 2023 03:43:37 GMT
Tue, 07 Mar 2023 03:43:37 GMT
Silverchair
jamams@jamanetwork.org
support@www.igerbera.com
-
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
//www.igerbera.com/journals/jamadermatology/fullarticle/2766772
Sat, 01 Aug 2020 00:00:00 GMT
This randomized clinical trial investigates the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis.
156
8
863
873
10.1001/jamadermatol.2020.1406
2766772
-
Efficacy and Safety of Lebrikizumab in Adults With Moderate to Severe Atopic Dermatitis
//www.igerbera.com/journals/jamadermatology/fullarticle/2761466
Wed, 01 Apr 2020 00:00:00 GMT
This phase 2b, placebo-controlled, randomized clinical trial evaluates the efficacy and safety of lebrikizumab, a novel, high-affinity, monoclonal antibody targeting interleukin (IL)–13 that selectively prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex, in adults with moderate to severe atopic dermatitis.
156
4
411
420
10.1001/jamadermatol.2020.0079
2761466
-
Baricitinib Combined With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis
//www.igerbera.com/journals/jamadermatology/fullarticle/2771084
Tue, 01 Dec 2020 00:00:00 GMT
This randomized clinical trial assesses the efficacy and safety of 4 mg and 2 mg of baricitinib in combination with background topical corticosteroid therapy in adults with moderate to severe AD who previously had an inadequate response to topical corticosteroid therapy.
156
12
1333
1343
10.1001/jamadermatol.2020.3260
2771084
-
Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
//www.igerbera.com/journals/jamadermatology/fullarticle/2782803
Wed, 01 Sep 2021 00:00:00 GMT
This randomized clinical trial assesses the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis.
157
9
1047
1055
10.1001/jamadermatol.2021.3023
2782803
-
Chilblains, an Indirect Dermatologic Consequence of the COVID-19 Pandemic
//www.igerbera.com/journals/jamadermatology/fullarticle/2767774
Tue, 01 Sep 2020 00:00:00 GMT
This case series describes 31 patients, most of them teenagers or young adults, who presented with chilblains during the COVID-19 pandemic.
156
9
998
1003
10.1001/jamadermatol.2020.2368
2767774
-
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine
//www.igerbera.com/journals/jamadermatology/fullarticle/2779643
Tue, 01 Jun 2021 00:00:00 GMT
This case-series study describes the clinical course and histopathologic examination findings for delayed localized cutaneous injection-site reactions to the Moderna COVID-19 vaccine.
157
6
716
720
10.1001/jamadermatol.2021.1214
2779643
-
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Plaque Psoriasis
//www.igerbera.com/journals/jamadermatology/fullarticle/2763686
Mon, 01 Jun 2020 00:00:00 GMT
This randomized clinical trial evaluates the safety and efficacy of risankizumab use for 2 years in patients with moderate to severe plaque psoriasis.
156
6
649
658
10.1001/jamadermatol.2020.0723
2763686
-
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic
//www.igerbera.com/journals/jamadermatology/fullarticle/2773121
Mon, 01 Feb 2021 00:00:00 GMT
This retrospective case series describes a systematic assessment of 40 patients with chilblain-like lesions durring the coronavirus 2019 pandemic and examines the association of these lesions with a viral-induced type I interferonopathy.
157
2
202
206
10.1001/jamadermatol.2020.4324
2773121
-
Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
//www.igerbera.com/journals/jamadermatology/fullarticle/2765614
Wed, 01 Jul 2020 00:00:00 GMT
This case report describes a 48-year-old man who presented with a rash on the buttocks, popliteal fossae, proximal anterior thighs, and lower abdomen following the onset of a fever.
156
7
820
822
10.1001/jamadermatol.2020.1741
2765614
-
Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis
//www.igerbera.com/journals/jamadermatology/fullarticle/2760694
Wed, 01 Apr 2020 00:00:00 GMT
This systematic review and meta-analysis evaluates the association between cancer and psoriasis or psoriatic arthritis.
156
4
421
429
10.1001/jamadermatol.2020.0024
2760694
-
Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis
//www.igerbera.com/journals/jamadermatology/fullarticle/2765026
Mon, 01 Jun 2020 00:00:00 GMT
This systematic review and network meta-analysis compares the effectiveness and safety of systemic immunomodulatory treatments for adult patients with atopic dermatitis.
156
6
659
667
10.1001/jamadermatol.2020.0796
2765026
-
Digitate Papulosquamous Eruption Associated With SARS-CoV-2 Infection
//www.igerbera.com/journals/jamadermatology/fullarticle/2765613
Wed, 01 Jul 2020 00:00:00 GMT
This case report describes an elderly patient who developed a squamous and erythematous periumbilical patch followed by digitate scaly thin plaques and papular lesions in conjunction with severe acute respiratory syndrome coronavirus 2 infection.
156
7
819
820
10.1001/jamadermatol.2020.1704
2765613
-
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne
//www.igerbera.com/journals/jamadermatology/fullarticle/2765025
Mon, 01 Jun 2020 00:00:00 GMT
This review of 2 randomized clinical trials assesses the safety and efficacy of topical clascoterone cream, 1%, a novel androgen receptor inhibitor for acne treatment.
156
6
621
630
10.1001/jamadermatol.2020.0465
2765025
-
Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening
//www.igerbera.com/journals/jamadermatology/fullarticle/2762711
Fri, 01 May 2020 00:00:00 GMT
This qualitative study examines how the use of artificial intelligence as a screening tool is perceived by patients receiving care in a dermatology clinic.
156
5
501
512
10.1001/jamadermatol.2019.5014
2762711
-
Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic
//www.igerbera.com/journals/jamadermatology/fullarticle/2767773
Tue, 01 Sep 2020 00:00:00 GMT
这种情况下系列描述了20名儿童和adolescents who presented with new-onset acral inflammatory lesions during the COVID-19 pandemic.
156
9
992
997
10.1001/jamadermatol.2020.2340
2767773
-
Mucocutaneous Manifestations of Multisystem Inflammatory Syndrome in Children
//www.igerbera.com/journals/jamadermatology/fullarticle/2773994
Mon, 01 Feb 2021 00:00:00 GMT
This case series describes the mucocutaneous findings seen in children with multisystem inflammatory syndrome in children during the height of the coronavirus disease 2019 (COVID-19) pandemic in New York City in 2020.
157
2
207
212
10.1001/jamadermatol.2020.4779
2773994
-
Enanthem in Patients With COVID-19 and Skin Rash
//www.igerbera.com/journals/jamadermatology/fullarticle/2768252
Thu, 01 Oct 2020 00:00:00 GMT
This case series describes the appearance of enanthem (oral cavity lesions) in patients with COVID-19.
156
10
1134
1136
10.1001/jamadermatol.2020.2550
2768252
-
Secukinumab Therapy for Netherton Syndrome
//www.igerbera.com/journals/jamadermatology/fullarticle/2766014
Sat, 01 Aug 2020 00:00:00 GMT
This case series evaluates the clinical response to treatment with the interleukin 17 antagonist secukinumab in patients with Netherton syndrome.
156
8
907
911
10.1001/jamadermatol.2020.1019
2766014
-
Evaluation of Sex-Specific Incidence of Melanoma
//www.igerbera.com/journals/jamadermatology/fullarticle/2763192
Fri, 01 May 2020 00:00:00 GMT
这个横断面研究考察了发病率of melanoma in men vs women between differing geographic locations, ages, and anatomic sites.
156
5
553
560
10.1001/jamadermatol.2020.0470
2763192
-
Prevalence of Hidradenitis Suppurativa
//www.igerbera.com/journals/jamadermatology/fullarticle/2780049
Sun, 01 Aug 2021 00:00:00 GMT
This systematic review and meta-analysis estimates worldwide hidradenitis suppurativa prevalence.
157
8
924
931
10.1001/jamadermatol.2021.1677
2780049
-
Psoriasis Prevalence in Adults in the United States
//www.igerbera.com/journals/jamadermatology/fullarticle/2781378
Sun, 01 Aug 2021 00:00:00 GMT
This cross-sectional study uses data from the National Health and Nutrition Examination Survey to assess the prevalence of psoriasis in adults in the US and how it has changed since 2003.
157
8
940
946
10.1001/jamadermatol.2021.2007
2781378
-
Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines
//www.igerbera.com/journals/jamadermatology/fullarticle/2781364
Sun, 01 Aug 2021 00:00:00 GMT
This cohort study examines cutaneous reactions in hospital employees who received messenger RNA COVID-19 vaccination.
157
8
1000
1002
10.1001/jamadermatol.2021.2114
2781364
-
Association Between Medication Use and Bullous Pemphigoid
//www.igerbera.com/journals/jamadermatology/fullarticle/2767250
Sat, 01 Aug 2020 00:00:00 GMT
This systematic review and meta-analysis assesses the association of the use of certain classes of medications among patients and the development of bullous pemphigoid.
156
8
891
900
10.1001/jamadermatol.2020.1587
2767250
-
Prognostic Gene Expression Profiling in Cutaneous Melanoma
//www.igerbera.com/journals/jamadermatology/fullarticle/2768743
Tue, 01 Sep 2020 00:00:00 GMT
This consensus statement assesses what evidence is needed to develop guidelines on integration of gene expression profile testing into cutaneous melanoma management.
156
9
1004
1011
10.1001/jamadermatol.2020.1729
2768743
-
Early Severe Cardiovascular Events and the Initiation of Ustekinumab
//www.igerbera.com/journals/jamadermatology/fullarticle/2770560
Sun, 01 Nov 2020 00:00:00 GMT
This case-time-control analysis uses data from the French national health insurance database to assess whether the initiation of ustekinumab treatment is associated with triggering severe cardiovascular events.
156
11
1208
1215
10.1001/jamadermatol.2020.2977
2770560
-
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
//www.igerbera.com/journals/jamadermatology/fullarticle/2790344
Sun, 01 May 2022 00:00:00 GMT
This epidemiological assessment uses the GLOBOCAN database to evaluate the numbers of new cases and deaths due to cutaneous melanoma globally and by world region in 2020 and to estimate global values in 2040.
158
5
495
503
10.1001/jamadermatol.2022.0160
2790344
-
Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19
//www.igerbera.com/journals/jamadermatology/fullarticle/2768760
Tue, 01 Sep 2020 00:00:00 GMT
This case series describes livedo racemosa and retiform purpura as cutaneous findings in patients with COVID-19.
156
9
1022
1024
10.1001/jamadermatol.2020.2800
2768760
-
Suicidality and Psychological Adverse Events in Patients Treated With Finasteride
//www.igerbera.com/journals/jamadermatology/fullarticle/2772818
Fri, 01 Jan 2021 00:00:00 GMT
This case-control study investigates the association of suicidality (ideation, attempt, and completed suicide) and psychological adverse events (depression and anxiety) with use of finasteride in a global database.
157
1
35
42
10.1001/jamadermatol.2020.3385
2772818
-
UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color
//www.igerbera.com/journals/jamadermatology/fullarticle/2774113
Mon, 01 Feb 2021 00:00:00 GMT
This systematic review critically assesses and synthesizes the published data regarding the association between UV exposure and the risk of cutaneous melanoma in skin of color.
157
2
213
219
10.1001/jamadermatol.2020.4616
2774113
-
Factors Associated With Short-term Relapse of Pemphigus After Rituximab First-line Therapy
//www.igerbera.com/journals/jamadermatology/fullarticle/2762874
Fri, 01 May 2020 00:00:00 GMT
This post hoc analysis of a randomized clinical trial examines factors associated with short-term relapse in patients with pemphigus treated with rituximab.
156
5
545
552
10.1001/jamadermatol.2020.0290
2762874